89988-08-9

Upstream product

• 24207-66-7 2,4,6-trichlorothiophenol 
• 634-93-5 2,4,6-trichloroaniline 
• 6324-50-1 1,3,5-trichloro-2-iodobenzene 
• 51527-73-2 2,4,6-trichlorobenzenesulfonyl chloride 

Downstream Products

• 17162-47-9 2,4,6-Trichlor-phenylsulfensaeure-chlorid 
• 876461-42-6 C₁₅H₁₂Cl₃N₃S 
• 143535-55-1 1-(Dimethylsulfamoyl)-4-fluoro-5-(2,4,6-trichlorophenylthio)pyrazole 
• 17154-21-1 2.4.6-Trichlor-phenylsulfensaeure-triphenylphosphoranylidenamid 
• 17162-41-3 2,4,6-trichlorosulfenamide 

Relevant academic research and scientific papers

Dithioates of Meldrum's acid, dimedone, and barbituric acid, novel sulfur transfer reagents for the one-pot copper-catalyzed conversion of aryl iodides into diaryl disulfides

We report herein the first application of CH-acid dithioates as sulfur transfer reagents. A new route for the synthesis of diaryldisulfides using the copper-catalyzed conversion of aryl iodides in the presence of Melderum's acid, dimedone or barbituric acid dithioates is discussed.

Continued exploration of the triazolopyridine scaffold as a platform for p38 MAP kinase inhibition

The structure based drug design, synthesis and structure-activity relationship of a series of C6 sulfur linked triazolopyridine based p38 inhibitors are described. The metabolic deficiencies of this series were overcome through changes in the C6 linker fr

NOVEL TRIAZOLOPYRIDINE COMPOUNDS

This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula (I): wherein R

NOVEL TRIAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION

This invention is directed generally to triazolopyridine compounds that generally inhibit p38 kinase, TNF, and/or cyclooxygenase activity. Such triazolopyridine include compounds generally corresponding in structure to the following formula (I): Wherein R1, R2, R3, R4, and R5are as defined in this specification. This invention also is directed to compositions of such triazolopyridines (particularly pharmaceutical compositions), intermediates for the syntheses of such triazolopyridines, methods for making such triazolopyridines, and methods for treating (including preventing) conditions (typically pathological conditions) associated with p38 kinase activity, TNF activity, and/or cyclooxygenase-2 activity.